High Point Advisor Group LLC Kazia Therapeutics LTD Transaction History

High Point Advisor Group LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 12, 2021	SELL	$8.98 - $12.86 $291,266 - $417,114	-32,435 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$5.61 - $13.47 $33,660 - $80,820	-6,000 Reduced 15.61%	32,435 $368,000
Q3 2020 Nov 06, 2020	BUY	$3.33 - $8.26 $19,980 - $49,560	6,000 Added 18.5%	38,435 $230,000
Q1 2020 May 01, 2020	BUY	$2.72 - $4.64 $87,972 - $150,071	32,343 Added 35155.43%	32,435 $92,000
Q1 2020 Apr 27, 2020	SELL	$2.72 - $4.64 $87,972 - $150,071	-32,343 Reduced 99.72%	92 $32.4 Million
Q3 2019 Nov 12, 2019	BUY	$2.33 - $3.83 $75,573 - $124,226	32,435 New	32,435 $96,000

2.09M

93.2K

Ticker KZIA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,111,300
Market Cap $22.2M
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...

Get notified when there are updates to the investment portfolio of High Point Advisor Group LLC, based on Form 13F filings with the SEC.

Stay updated on High Point Advisor Group LLC with notifications on news.